DaVita Stock (NYSE:DVA), Trade Ideas

DaVita

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

DaVita Inc

BrandywineGLOBAL-Dynamic US Large Cap Value ETF

Dovarri Inc

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

Philips (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phg#NYSE">PHG</a>) is leaving no stone unturned to bolster its patient monitoring solutions portfolio on the back of recent collaborations. 
In this regard, the company partnered with smartQare to integrate the latter&#39;s viQtor solution into its clinical patient monitoring platforms. 
This partnership aims to improve continuous patient monitoring in and out of hospitals by enabling open communication between sensors and systems, making data and decision support accessible via user-friendly platforms. 
Moreover, as a part of the deal, smartQare will acquire Philips&#39; Healthdot business to combine its viQtor patient monitoring solution with the latter&#39;s wearable biosensors, offering integrated remote monitoring to healthcare providers and patients. 
Philips is expected to gain solid traction across hospitals and other healthcare organizations on the back of its latest move.
<div class="chart_embed">
<h3>Koninklijke Philips N.V. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/PHG/price-consensus-chart?icid=chart-PHG-price-consensus-chart"><img alt="Koninklijke Philips N.V. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/a8/1712581770.png" style="height:285px; width:620px" title="" /> </a>
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
</div>
<h3>Strengthening Patient Monitoring Solutions</h3>
Apart from the smartQare partnership, the company recently introduced Philips Capsule Surveillance to strengthen its patient monitoring solutions portfolio. 
This system offers a comprehensive view of patient status, enabling tailored alerts and decision-making, overcoming cognitive overload challenges in complex hospital environments. 
Further, Philips unveiled Visual Patient Avatar, a new monitoring solution to help clinicians in the operating room with complex patient data and time constraints. 
This new solution is designed to improve situational awareness in operating rooms by visualizing vital information about the patients through animations, colors and shapes. The user-friendly avatar display enhances the recall and processing of critical data, potentially saving lives and providing clinical teams with peace of mind. 
Additionally, Philips received 510(k) clearance for its IntelliVue patient monitor software, including the award-winning Philips Sounds alarm package, making it available in the United States and over 200 countries worldwide. This will enable the company to create a more peaceful, healing environment for both patients and caregivers.
<h3>Wrapping Up</h3>
All the above-mentioned endeavors will enable Philips to capitalize on growth opportunities present in the global patient monitoring solutions market. A Vynz Research report predicts the global patient monitoring solutions market to reach $38.95 billion, implying a CAGR of 7.8% during the forecast period of 2023-2030. 
Moreover, the strengthening patient monitoring solutions portfolio is expected to benefit the Connected Care segment, which, in turn, will likely aid the overall financial performance of the company in the upcoming period. 
Philips expects 2024 comparable sales growth in the band of 3-5%. 
The Zacks Consensus Estimate for 2024 sales is pegged at $20.12 billion, indicating growth of 2.4% from the year-ago quarter.
<h3>Zacks Rank &amp; Stock to Consider</h3>
Currently, Philips carries a Zacks Rank #3 (Hold). 
Its shares have lost 13.9% in the year-to-date period, underperforming the Zacks Medical sector&#39;s growth of 4.2%. 
Some better-ranked stocks in the broader medical market sector are DaVita (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Cardinal Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>), and AdaptHealth (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahco#NASDAQ">AHCO</a>). While DaVita sports a Zacks Rank #1 (Strong Buy) at present, Cardinal Health and AdaptHealth carry a Zacks Rank #2 (Buy) each. 
DaVita shares have surged 27.5% in the year-to-date period. DVA&#39;s long-term earnings growth rate is currently projected at 12.15%. 
Cardinal Health shares have gained 9% in the year-to-date period. CAH&#39;s long-term earnings growth rate is currently projected at 14.25%. 
AdaptHealth shares have gained 43.6% in the year-to-date period. The long-term earnings growth rate for AHCO is currently projected at 14.90%.
<a href="https://www.zacks.com/stock/news/2252014/philips-phg-boosts-patient-monitoring-with-smartqare-deal?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-2252014">To read this article on Zacks.com click here.</a>

News

Health Care

Small Cap

Markets

Trading Ideas

General

AHCO

Philips (PHG) Boosts Patient Monitoring With SmartQare Deal

After wrapping up a robust first quarter on strong corporate profits, enthusiasm around AI and hopes that the Fed will cut rates, Wall Street&#39;s rally fizzled out to start Q2 on uncertainty over the timing of rate cuts. 
Let us examine the health of the U.S. economy ahead on the World Health Day and bring to investors&#39; attention the key developments and some solid picks for a robust investment portfolio. 
Similar to the six vital nutrients required for good health, six pillars support the economy. Here, we have picked six essential market nutrients in the form of sectors and then zeroed in on stocks that have a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a higher market cap in their respective sectors using the Zacks Stock Screener. Other parameters considered include a VGM Score of B or better, positive current-year earnings estimate revisions over the past 30 or 60 days, positive current-year EPS growth, and a place in a top-ranked Zacks industry (in the top 45%).
<h3>Vitamins: Consumer Sector</h3>
The consumer sector has been enjoying strong optimism led by stronger spending power, wage growth and a lower unemployment rate. The potential rate cuts will lead to reduced borrowings, thereby increasing consumer spending. It will also lead to higher demand for all types of products and services in the economy, taking the consumer sector higher. This will continue to give the economy its regular dose of vitamins. 
Within this sector, Lancaster Colony Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lanc#NASDAQ">LANC</a>), a manufacturer and marketer of specialty food products for the retail and foodservice markets, is a great pick for investors. 
This Zacks Rank #2 company saw a positive earnings estimate revision of 21 cents over the past 60 days for this fiscal year (ending June 2024). It has an expected earnings growth rate of 34%. Lancaster Colony belongs to a top-ranked Zacks industry (top 28%) and has a VGM Score of B, suggesting its potential for solid growth in the months ahead. The stock has gained about 22% over the past three months.
<h3>Proteins: Financial Sector</h3>
Like protein, the financial sector, helps in carrying out a huge array of functions through its banks and financial institutions. The sector facilitates growth in every part of the country. The stocks in this sector have shown immense strength courtesy of a resilient economy and a steep yield curve. 
Travelers Companies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/trv#NYSE">TRV</a>) has climbed about 19% over the past three months and could represent a good buying opportunity. It is principally engaged, through its subsidiaries, in providing a wide variety of property and casualty insurance and surety products and services to businesses, organizations and individuals in the United States and select international markets. The Zacks Consensus Estimate for 2024 has been revised by a couple of cents over the past 30 days and indicates substantial year-over-year growth of 34.8%. This Zacks Rank #2 company falls within a top-ranked Zacks industry (top 9%) and has a VGM Score of B.
<h3>Minerals: Medical Sector</h3>
Just like minerals are important for bone structure, healthcare is crucial to the economy. In fact, it is the backbone of an economy. Healthcare is one of the largest and fastest-growing sectors thanks to an aging population, growing middle class, and insatiable demand for new treatments and drugs for many illnesses. About 10% of economic growth comes from this sector. 
The industry is currently benefiting from encouraging trends, including cutting-edge medicines, new drug approvals, accelerated pace of innovation, promising drug launches, cost-cutting efforts, an aging population, technological advancements, expanding insurance coverage, the rising middle class, demand for new drugs, and ever-increasing healthcare spending. Continuous innovation in medical technology, including telemedicine, AI in diagnostics, and personalized medicine, is improving patient care and operational efficiency. One of the beneficiaries of this trend is Zacks Ranked #1 player DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) from a top-ranked Zacks industry (top 37%), gaining 23.4% over the past three months. 
This is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease. It saw solid earnings estimates of 26 cents for this year over the past 30 days to $9.23, indicating year-over-year growth of 9%. The stock has a VGM Score of B.
<h3>Carbohydrates: Technology Sector</h3>
Similar to carbs that provide energy to the muscles and brain, the technology sector powers the economy with its wide range of products and services, including electronics, software, computers and social media. The sector has been performing well this year on the continued AI boom and strong corporate earnings. As the tech sector relies on borrowing for superior growth, it is cheaper to borrow more money for further initiatives when interest rates are low. The expansion of AI applications holds the promise of ushering in fresh opportunities for growth within the sector. Hopes of cutting interest rates later this year are also adding to the strength. 
Within the sector, Uber Technologies (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>), with a Zacks Rank #2 and a VGM Score of B, seems a solid choice. It develops and operates proprietary technology applications in the United States and has expanded its presence in multiple countries across the globe, including Canada, Latin America, Europe, the Middle East and Asia (excluding China). The stock, which belongs to a top-ranked Zacks industry (top 25%), saw a positive earnings estimate revision of 15 cents over the past 30 days for this year and has an expected earnings growth rate of 36.8%. It has gained nearly 23% over the past three months.
<h3>Fats: Construction Sector</h3>
The construction sector &mdash; accounting for 5.5% of GDP &mdash; provides energy backup to the economy. This is because construction activity picks up when the economy strengthens. The sector has been doing well on lower mortgage rates, which is encouraging people to buy more homes and has made refinancing cheaper. Notably, U.S. homebuilders are now feeling more confident than they have since last summer. 
To tap this bullish trend, Sherwin-Williams Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shw#NYSE">SHW</a>), which manufactures and sells paints, coatings and related products, primarily in North and South America, could be an exciting pick. The company&#39;s earnings estimates have gone up by 5 cents over the past month for this year. The current Zacks Consensus Estimate is pegged at $11.49, up 11% year over year. Sherwin-Williams has a Zacks Rank #2 and a VGM Score of B, It belongs to a top-ranked Zacks industry (top 37%). Shares of SHW are up nearly 12% over the past three months.
<h3>Water: Transport Sector</h3>
Transport enables the smooth movement of freight and passengers through different modes such as rail, trucks, ships and air. It occupies an important place in the world market and is often considered a barometer of broad economic health. The transport sector is seeing a surge on a rise in global travel demand. 
SkyWest (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/skyw#NASDAQ">SKYW</a>) operates as a regional airline in the United States through its subsidiary SkyWest Airlines. The stock has seen a positive earnings estimate revision of $1.00 for this year over the past month 60 days and has estimated earnings growth of 729.9%. SkyWest has a Zacks Rank #1 and a VGM Score of A. It belongs to a top-ranked Zacks industry (top 19%). The stock has tumbled more than 37% over the past three months.
<a href="https://www.zacks.com/stock/news/2251081/diagnosing-the-economy-ahead-of-world-health-day-6-picks?cid=CS-BENZ-FT-analyst_blog|investment_ideas-2251081">To read this article on Zacks.com click here.</a>

LANC

SKYW

UBER

Diagnosing the Economy Ahead of World Health Day: 6 Picks

Globus Medical (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gmed#NYSE">GMED</a>) continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company is expanding in the overseas markets through the expansion of direct and distributor sales force. Yet, we are worried about a challenging macroeconomic scenario that continues to plague Globus Medical&#39;s profit margins. It has a Zacks Rank #3 (Hold) at present.
GMED is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories, and unique surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures. 
The company is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings. Over the past couple of quarters, this business has registered above-market growth, driven by competitive rep recruiting from prior quarters and robotic pull-through. 
In the fourth quarter, Legacy Globus&#39; musculoskeletal revenues surged 11.8%. The growth was led by the company&#39;s U.S. and international spine businesses, as well as continued share growth within trauma. 
Earlier, Globus Medical launched three new products &mdash; REFLECT, MARVEL and Ossifuse. The company continues to make significant progress in launching its prone, lateral patient positioning system. As the company moves into 2024, it anticipates a strong cadence of product launches throughout the Musculoskeletal portfolio.
<div class="chart_embed">
<h3>Globus Medical, Inc. Price</h3>
<a href="https://www.zacks.com/stock/chart/GMED/fundamental/price?icid=chart-GMED-fundamental/price"><img alt="Globus Medical, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/63/1712230792.png" style="height:251px; width:538px" title="" /> </a>
Globus Medical, Inc. price | Globus Medical, Inc. Quote
</div>
Globus Medical merged its business with NuVasive. The combined company forms a global musculoskeletal business, focused on rapid innovation, addressing unmet clinical needs and improving offerings to surgeons and patients. It capitalizes on GMED&#39;s complementary commercial organization and should allow the company to accelerate its globalization strategies to increase customer reach and strengthen surgeon relationships. 
The combined company is working to bring the best-in-class technologies to create a differentiated and comprehensive procedural solution offering as part of its approach to address unmet clinical needs and support surgeons and patients. According to Globus Medical, both the companies&#39; operational footprints are highly complementary, allowing them to better leverage each other&#39;s manufacturing and supply-chain resources to increase internal production while reducing the amount of required stand-alone capital investment. This way, they can redirect investments and improve cash flow. 
In terms of the latest development, NuVasive stand-alone sales for the fourth quarter were up 2% on a pro forma basis. This was primarily driven by continued market penetration in the international spine with 14% growth, market re-entry of key technology of NuVasive Specialty Orthopedics delivering 26% gains, and strengthening NuVasive Clinical Services increasing 6% from the prior- year level.
On the flip side, Globus Medical, like other industry players, is currently fighting negative trends in the global economy, including interest rate fluctuations, increases in inflation and financial market volatility. These factors are adversely impacting the company&#39;s operations and financial performance. The global inflation, in particular, has led to a significant rise in the cost of raw materials for the company. In the fourth quarter, GMED witnessed a 276.1% surge in the cost of goods sold. 
These macroeconomic factors, along with the rising wage and raw material costs, are also leading to a significant escalation in the company&#39;s operating expenses. SG&amp;A expenses in the reported quarter were up 107.3% from the year-ago quarter&#39;s level. Research and development expenses increased 167.9% year over year.
Meanwhile, the presence of a large number of players made the musculoskeletal devices market intensely competitive. The orthopedic industry, in particular, is highly competitive with the presence of more prominent players like Zimmer Biomet, Stryker, Johnson &amp; Johnson&#39;s DePuy, Smith &amp; Nephew and Medtronic. Globus Medical needs to constantly introduce or acquire new products to withstand the competitive pressure and maintain its market share.
<h3>Key Picks</h3>
Some better-ranked stocks in the broader medical space are DaVita (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Stryker (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) and Cardinal Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>). While DaVita presently sports a Zacks Rank #1 (Strong Buy), Stryker and Cardinal Health carry a Zacks Rank #2 (Buy) each.
DaVita&#39;s shares have risen 65.3% in the past year. Earnings estimates for DaVita have risen from $8.97 per share to $9.23 in 2024 and from $9.77 to $10.01 in 2025 in the past 30 days.
DVA&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 35.6%. In the last reported quarter, it posted an earnings surprise of 22.2%.
Estimates for Stryker&#39;s 2024 earnings per share (ETF:EPS) have remained constant at $11.86 in the past 30 days. Shares of the company have risen 21.5% in the past year compared with the industry&#39;s growth of 4,6%.
SYK&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%. In the last reported quarter, it delivered an earnings surprise of 5.8%.
Estimates for Cardinal Health&#39;s 2024 EPS have moved up to $7.29 from $7.28 in the past 30 days. Shares of the company have surged 45% in the past year compared with the industry&#39;s 11.7% growth.
CAH&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%. In the last reported quarter, it delivered an earnings surprise of 16.7%.
<a href="https://www.zacks.com/stock/news/2250489/globus-medical-gmed-gains-from-new-launches-amid-macro-issues?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2250489">To read this article on Zacks.com click here.</a>

GMED

Globus Medical (GMED) Gains From New Launches Amid Macro Issues

Efforts to advance chronic disease prevention through enhanced education, awareness and support — kicking off during National Kidney Month &nbsp;
DENVER, March 11, 2024 /PRNewswire/ -- Today,&nbsp;The American Diabetes Association &#xAE; (ADA) and DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of the most prevalent chronic conditions in the U.S. — diabetes and chronic kidney disease (CKD). The kick-off for this expanded effort coincides with National Kidney Month, a time when both organizations bolster efforts to increase kidney health awareness and education.
Chronic disease is the leading cause of death and disability in the United States.[1]&nbsp;More than 38 million Americans are living with diabetes, and approximately one in three American adults with diabetes has CKD.[2]&nbsp;Because the symptoms of CKD are often mild and go undetected, it's critical for individuals to understand their risk factors and take necessary steps to protect their health.
"At DaVita, we say we're a community first and a company second, underscoring our deep-rooted commitment to creating healthier communities," said Dr. Jeff Giullian, chief medical officer for DaVita. "By combining our expertise in kidney care with the ADA's leadership in diabetes education, we aim to make a lasting impact on chronic disease prevention, specifically in the communities that need it most."
As part of this expansion, DaVita has contributed an additional $1.5 million to bolster the ADA's initiatives targeting individuals at risk of or who have diabetes and CKD, focused on driving hyperlocal and culturally relevant awareness and engagement in particular within communities of greater need.
Diabetes and CKD disproportionately affect many communities of color, including Black and Hispanic or Latino populations. The two organizations are dedicated to improving health equity by uncovering new ways to drive awareness in underserved communities, addressing disparities and barriers to care, and mitigating clinical biases. The efforts include developing materials in multiple languages, learning personal cultural context for lifestyles and dietary considerations, and identifying barriers that these communities face.
Together, the ADA and&nbsp;DaVita will:
<ul>
<li>Create a digital home base with new educational materials that are easily accessible for patients and health care professionals.</li>
<li>Pilot a registered dietitian (RDs) program enabling greater access to diabetes education and resources to keep RDs well-informed to better care for patients.</li>
<li>Sponsor the ADA's State of Diabetes events in high-priority markets where DaVita and ADA leaders will lead discussions around some of the most important topics facing their shared patient populations in today's health care system.</li>
</ul>
"Through our work with DaVita, we have informed and educated millions of Americans — but our work isn't finished," said&nbsp;Charles "Chuck" Henderson, chief executive officer at the ADA. "We must continue the momentum and create more opportunities to promote diabetes and CKD education, especially in high-need communities with marginalized populations."
To further celebrate National Kidney Month in March, DaVita has launched a campaign that focuses on "Connecting the Dots" between kidney health and other chronic conditions, including diabetes. On March 26, DaVita dietitians will join the ADA for a live cooking class featuring a tasty diabetes- and kidney-friendly meal. Learn more and register <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4112732-1&amp;h=1817832524&amp;u=https%3A%2F%2Fhomemadecooking.com%2Fclass%2Fhealthy-stir-fry-masterclass%2F&amp;a=here">here</a>.
For more information and resources from the ADA and DaVita, check out the latest edition of their co-created online kidney care journey at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4112732-1&amp;h=4046936685&amp;u=https%3A%2F%2Fwww2.diabetes.org%2Fkidney-care%3Fs_src%3Dvanity%26s_subsrc%3Dkidney&amp;a=diabetes.org%2Fkidney">diabetes.org/kidney</a>.

Biotech

The American Diabetes Association And DaVita  Announce Expansion Of A Multi-Year Collaboration, Focused On Advancing Chronic Disease Prevention, Specifically Addressing Diabetes And Chronic Kidney Disease

Barclays analyst Sarah James initiates coverage on DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) with a Equal-Weight rating and announces Price Target of $133.

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On DaVita with Equal-Weight Rating, Announces Price Target of $133

Tuesday,&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released the headline results from the kidney outcomes trial, FLOW.
The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people treated with semaglutide <a href="https://www.benzinga.com/general/biotech/24/03/37478859/novo-nordisk-says-famed-diabetes-medicine-ozempic-reduces-risk-of-kidney-disease-progression-data" target="_blank" rel="noreferrer noopener">1.0 mg compared to placebo</a>. 
Stocks of kidney dialysis-focused DaVita Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>), and Baxter International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) shares fell sharply when Novo Nordisk stopped the semaglutide kidney outcomes trial FLOW based on early signs of <a href="https://www.benzinga.com/news/large-cap/23/10/35190991/whats-going-on-with-kidney-dialysis-provider-stocks-today" target="_blank" rel="noreferrer noopener">efficacy in October last year</a>.
Whereas, kidney dialysis stocks are trading higher today as Novo Nordisk&#8217;s popular diabetes drug, Ozempic, fell short of some expectations.
Citing J.P.Morgan analyst, Reuters noted, &#8220;We see 24% as at the low end of expectations &#8211; that is, there were some fears out there that the impact could have been higher,&#8221; adding that this could be contributing to the relief in Fresenius&#8217; shares.
DaVita and German competitor Fresenius have downplayed concerns regarding GLP-1 drugs like Ozempic and Wegovy, which exhibit significant advancements in treating obesity and diabetes. The emergence of these drugs has led to a contraction in the kidney care market.
In October, citing&nbsp;Citi&nbsp;analyst, Reuters noted that GLP-1 drugs could &#8220;potentially negatively impact&#8221; the size of the dialysis patient population over time.
Price Action: DVA shares are up 7.99% at $135.78, FMS stock is up 11.4% at $20.80, and BAX shares are up 1.88% at $43.30 on the last check Tuesday.
Image By Natalia Varlei On Shutterstock

Large Cap

Movers

Why Are Dialysis Provider Stocks Trading Higher On Tuesday?

Shares of SOPHiA GENETICS SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soph#NASDAQ">SOPH</a>) fell sharply during Tuesday&rsquo;s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
Sophia Genetics posted GAAP loss of 37 cents per share, versus market expectations for a loss of 27 cents per share. The company&rsquo;s quarterly sales came in at $17.05 million, missing estimates of $17.33 million.
SOPHiA GENETICS shares tumbled 19% to $4.55 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) climbed 146.3% to $0.1106 after dipping 19% on Monday. Sunshine Biopharma recently announced closing of $10.0 million underwritten public offering.</li>
<li>Airship AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aisp#NASDAQ">AISP</a>) climbed 93.3% to $3.16 after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform.</li>
<li>Bruush Oral Care Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brsh#NASDAQ">BRSH</a>) surged 42.9% to $0.0686.</li>
<li>Apogee Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apge#NASDAQ">APGE</a>) shares jumped 41.6% to $59.10 after the company announced interim results from its Phase 1 healthy volunteer trial for APG777. Also, the company reported FY23 financial results.</li>
<li>Dave Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dave#NASDAQ">DAVE</a>) gained 39.8% to $30.62 after the company reported a year-over-year increase in fourth-quarter revenue results.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) rose 38.1% to $10.65.</li>
<li>Enviva Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eva#NYSE">EVA</a>) gained 26.4% to $0.6571.</li>
<li>AeroVironment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avav#NASDAQ">AVAV</a>) shares surged 24.8% to $163.05 after the company reported better-than-expected results for its fourth quarter. The company said it sees FY24 adjusted earnings of $2.69 to $2.83 per share on revenue of $700 million to $710 million.</li>
<li>INNOVATE Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vate#NASDAQ">VATE</a>) rose 24.4% to $0.90. The company reported fourth quarter financial results.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) climbed 24.3% to $5.07.</li>
<li>Paymentus Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pay#NYSE">PAY</a>) rose gained 20.3% to $19.67 after the company reported better-than-expected fourth quarter financial results.</li>
<li>BeyondSpring Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bysi#NASDAQ">BYSI</a>) gained 20.1% to $1.97.</li>
<li>bioAffinity Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biaf#NASDAQ">BIAF</a>) climbed 19.4% to $2.83. bioAffinity Technologies reported accelerating sales growth of CyPath&reg; Lung.</li>
<li>XORTX Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrtx#NASDAQ">XRTX</a>) gained 18.4% to $4.18.</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdio#NASDAQ">CDIO</a>) rose 17.9% to $1.52 after the company announced that the U.S. Patent and Trademark Office issued a notice of allowance for U.S. Application No. 17,857,723 Titled Compositions And Methods For Detecting Predisposition To Cardiovascular Disease.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) shares rose 17.2% to $14.56. Phunware shares jumped 75% on Monday amid volatility in Trump-related stocks after Donald Trump won the Missouri and Idaho Republican caucuses. Also, the Supreme Court ruled that Colorado can&#39;t remove Donald Trump from the Republican primary ballot in the state.</li>
<li>3D Systems Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ddd#NYSE">DDD</a>) jumped 14.7% to $4.7150. 3D Systems announced additional partial repurchase of convertible senior notes.</li>
<li>Fresenius Medical Care AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fms#NYSE">FMS</a>) gained 12.2% to $20.95. Fresenius Medical Care achieved next milestone in portfolio optimization program, announcing sale of dialysis clinics in Brazil, Colombia, Chile, Ecuador.</li>
<li>New York Community Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NASDAQ">NYCB</a>) gained 11.3% to $3.0411 after falling 23% on Monday. New York Community Bancorp last week announced that it identified material weaknesses in its internal controls and replaced its CEO.</li>
<li>Vicarious Surgical Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rbot#NYSE">RBOT</a>) rose 7.8% to $0.3880 after the company reported quarterly financial results.</li>
<li>DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) gained 7.4% to $135.14. DaVita entered into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador.</li>
<li>Momentus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnts#NASDAQ">MNTS</a>) shares rose 7% to $0.8345 after the company was awarded a contract from NASA.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quoin Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qnrx#NASDAQ">QNRX</a>) shares fell 46.2% to $1.56 after the company announced the pricing of a $6.5 million public offering.</li>
<li>Crawford &amp; Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crd-a#NYSE">CRD-A</a>) fell 27.7% to $9.04 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Ekso Bionics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ekso#NASDAQ">EKSO</a>) fell 24.8% to $1.58 after the company reported mixed fourth-quarter financial results.</li>
<li>ThredUp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tdup#NASDAQ">TDUP</a>) fell 23.3% to $1.8099 after reporting fourth-quarter results.</li>
<li>Lipella Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lipo#NASDAQ">LIPO</a>) fell 22.5% to $0.7909. Lipella Pharmaceuticals announced FDA clearance of IND for LP-410 for oral graft-versus-host disease, advancing clinical pipeline.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) fell 21% to $0.7983.</li>
<li>Eyenovia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eyen#NASDAQ">EYEN</a>) dipped 21% to $1.8006.</li>
<li>Semrush Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/semr#NYSE">SEMR</a>) fell 19.9% to $10.42 after the company reported fourth-quarter financial results.</li>
<li>BitFuFu Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fufu#NASDAQ">FUFU</a>) fell 19.3% to $10.60. BitFuFu shares jumped around 106% on Monday amid volatility following the company&#39;s recent business combination with Arisz Acquisition Corp and listing on the Nasdaq.</li>
<li>GitLab Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtlb#NASDAQ">GTLB</a>) shares fell 19.2% to $60.16 after the company issued FY25 earnings guidance below estimates.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) declined 19.2% to $4.58.</li>
<li>Yiren Digital Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yrd#NYSE">YRD</a>) fell 16.3% to $4.60.</li>
<li>Cara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cara#NASDAQ">CARA</a>) fell 16.2% to $0.8375 following downbeat fourth-quarter results.</li>
<li>Stitch Fix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfix#NASDAQ">SFIX</a>) shares dipped 15.7% to $2.7650 after the company reported worse-than-expected second-quarter financial results and issued a weak revenue forecast for FY24.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) fell 15.6% to $5.66.</li>
<li>Zhongchao Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcmd#NASDAQ">ZCMD</a>) fell 13.8% to $ 2.73.</li>
<li>CECO Environmental Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ceco#NASDAQ">CECO</a>) dipped 13.8% to $19.74 despite better-than-expected fourth-quarter financial results and raised guidance.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) shares declined 13.5% to $1.27. Renalytix shares jumped 41% on Monday after the company announced that it received an unsolicited approach from a publicly listed strategic diagnostics company.</li>
<li>Powell Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/powl#NASDAQ">POWL</a>) tumbled 12.4% to $161.88.</li>
<li>Vivakor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vivk#NASDAQ">VIVK</a>) shares fell 12.3% to $0.93 after jumping around 30% on Monday. Vivakor signed a definitive merger agreement with Empire Diversified Energy for a combined enterprise value of approximately $250 million.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) shares declined 12.1% to $1,172.93 after the company announced a proposed private offering of $600 million of convertible senior notes.</li>
<li>AxoGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) fell 12.1% to $9.31 following fourth-quarter financial results.</li>
<li>MingZhu Logistics Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ygmz#NASDAQ">YGMZ</a>) shares fell 11.2% to $0.4785 after gaining over 12% on Monday. MingZhu Logistics Holdings signed a non-binding letter of intent (LOI) to acquire driverless auto technologies and intellectual property (IP) portfolio valued between $80 million and $90 million.</li>
<li>Albemarle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>) shares fell 11.9% to $117.40 after the company announced a proposed public offering of depositary shares.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tndm#NASDAQ">TNDM</a>) dipped 11% to $27.73 after the company announced a proposed $250 million private placement of convertible notes due 2029.</li>
<li>Amer Sports, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/as#NYSE">AS</a>) fell 10.1% to $15.59 after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued FY24 EPS guidance below estimates.</li>
<li>Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) shares fell 9.8% to $1.28 after surging 35% on Monday.</li>
<li>Samsara Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iot#NYSE">IOT</a>) fell 9% to $32.65.</li>
<li>MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) fell 8.2% to $ 402.84.</li>
<li>Sprout Social, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spt#NASDAQ">SPT</a>) fell 8% to $58.96.</li>
<li>e.l.f. Beauty, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elf#NYSE">ELF</a>) declined 7.5% to $193.29.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/03/37481565/top-5-materials-stocks-that-are-ticking-portfolio-bombs"> Top 5 Materials Stocks That Are Ticking Portfolio Bombs </a>

Penny Stocks

Intraday Update

AIMD

AISP

APGE

AVAV

AXGN

BIAF

BRSH

BYSI

CARA

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CECO

CMAX

CRD-A

DAVE

EKSO

EYEN

FUFU

GTLB

LIPO

MNTS

MSTR

NYCB

OCEA

PHUN

POWL

QNRX

RBOT

RNLX

SBFM

SEMR

SFIX

SIDU

SOPH

TDUP

TNDM

VATE

VIVK

XRTX

YGMZ

ZCMD

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) rose during Tuesday&rsquo;s session following <a href="https://www.benzinga.com/news/earnings/24/03/37477000/nio-surpasses-q4-earnings-expectations-eyes-growth-with-new-electric-flagship-launch">upbeat quarterly results</a>.
NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter. Analysts, on average, estimated revenue of $2.29 billion for the quarter. Excluding share-based compensation expenses, the company reported an adjusted loss of (2.81) yuan or ($0.39) compared to (3.07) yuan in the year-ago quarter and (2.28) yuan in the third quarter of 2023. Analysts had called for a loss of $(0.51) per share.
NIO shares gained 3.6% to $5.52 on Tuesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Apogee Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apge#NASDAQ">APGE</a>) shares gained 41.6% to $59.10 after the company announced interim results from its Phase 1 healthy volunteer trial for APG777. Also, the company reported FY23 financial results.</li>
<li>Dave Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dave#NASDAQ">DAVE</a>) surged 39.8% to $30.62 after the company reported a year-over-year increase in fourth-quarter revenue results.</li>
<li>AeroVironment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avav#NASDAQ">AVAV</a>) shares climbed 24.8% to $163.05 after the company reported better-than-expected results for its fourth quarter. The company said it sees FY24 adjusted earnings of $2.69 to $2.83 per share on revenue of $700 million to $710 million.</li>
<li>Paymentus Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pay#NYSE">PAY</a>) rose 20.3% to $19.67 after the company reported better-than-expected fourth quarter financial results.</li>
<li>3D Systems Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ddd#NYSE">DDD</a>) climbed 14.7% to $4.7150. 3D Systems announced additional partial repurchase of convertible senior notes.</li>
<li>Fresenius Medical Care AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fms#NYSE">FMS</a>) rose 12.2% to $20.95. Fresenius Medical Care achieved next milestone in portfolio optimization program, announcing sale of dialysis clinics in Brazil, Colombia, Chile, Ecuador.</li>
<li>Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) gained 11.6% to $178.44.</li>
<li>New York Community Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NASDAQ">NYCB</a>) climbed 11.3% to $3.0411 after falling 23% on Monday. New York Community Bancorp last week announced that it identified material weaknesses in its internal controls and replaced its CEO.</li>
<li>Spyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/syre#NASDAQ">SYRE</a>) gained 11.3% to $38.92. Spyre Therapeutics recently reported a year-over-year increase in fourth-quarter EPS results.</li>
<li>The RealReal, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/real#NASDAQ">REAL</a>) rose 10.7% to $3.5450.</li>
<li>V2X, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vvx#NYSE">VVX</a>) gained 10.4% to $42.66 after the company reported better-than-expected fourth-quarter results and provided upbeat FY24 guidance.</li>
<li>Scholar Rock Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srrk#NASDAQ">SRRK</a>) rose 10.3% to $16.94.</li>
<li>Riskified Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rskd#NYSE">RSKD</a>) gained 8.8% to $ 4.97 after the company reported better-than-expected fourth-quarter EPS and revenue but issued guidance below estimates.</li>
<li>DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) rose 7.4% to $135.14. DaVita entered into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador.</li>
<li>Constellation Energy Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ceg#NASDAQ">CEG</a>) gained 4.9% to $184.63. On Monday, UBS maintained a Buy rating on the stock and raised its price target from $151 to $201.</li>
<li>Harley-Davidson, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hog#NYSE">HOG</a>) rose 4% to $38.14. DA Davidson analyst Brandon Rolle reiterated Harley-Davidson with a Buy and maintained a $42 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37458044/bitcoin-surpasses-65-000-pepe-emerges-as-top-gainer"> Bitcoin Surpasses $65,000; Pepe Emerges As Top Gainer</a>

KRYS

REAL

RSKD

SRRK

SYRE

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday

WIIM

Shares of dialysis stocks are trading higher in reaction to Novo Nordisk's Ozempic kidney disease data.

Expansion would make DaVita the largest dialysis services provider in Latin America
DENVER, March 5, 2024 /PRNewswire/ -- DaVita Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), a leading provider of kidney care services, today announced that it has agreed to terms on the expansion of its international operations in Brazil and Colombia, and its entry into Chile and Ecuador. The deal, which is consistent with DaVita&#39;s disciplined investment strategy, involves four separate acquisitions from Fresenius Medical Care for a total purchase price of $300M USD. The transaction in Chile closed effective today. The transactions in Ecuador, Colombia and Brazil remain subject to each country&#39;s respective anti-trust and regulatory approval processes, which are each expected to be completed at various times during 2024.
Upon completion of the transactions and when combined with DaVita&#39;s existing Latin American operations in Brazil and Colombia, the Company will have more than 15,000 DaVita teammates providing high-quality clinical care to more than 60,000 patients in more than 270 clinics. As a result, DaVita would become the largest dialysis services provider in Latin America.
&quot;As we welcome thousands of dedicated caregivers to DaVita, we will continue our strategy of combining our global clinical expertise with strong investment in our local teams to deliver a sustainable and valuable contribution to the healthcare communities we serve,&quot; said Robert Lang, president of DaVita International. &quot;Delivering outstanding clinical care for individuals suffering from kidney disease is our most important priority. We look forward to building on our existing market expertise and the established quality of these centers through this transition.&quot;
DaVita&#39;s international operations provide life-sustaining care in 12 countries outside of the United States and, assuming completion of the transactions announced today, will have grown from serving 23,000 patients in 2017 to serving more than 79,000 patients.

Global

DaVita Enters Into Agreement To Expand Operations In Brazil And Colombia, Enter Chile And Ecuador, Involving Four Separate Acquisitions From Fresenius Medical Care For A Total Purchase Price Of $300M

Javier Rodriguez, Chief Executive Officer at DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), disclosed an insider sell on February 28, according to a recent SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000927066/000092706624000028//Archives/edgar/data/927066/000092706624000028/0000927066-24-000028-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Rodriguez sold 345,142 shares of DaVita. The total transaction amounted to $43,363,753. 
Monitoring the market, DaVita's shares down by 0.39% at $126.48 during Thursday's morning.
<h3>About DaVita</h3>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
<h3>DaVita: Financial Performance Dissected</h3>
Positive Revenue Trend: Examining DaVita's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.85% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: With a high gross margin of 32.02%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): DaVita's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.67.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 10.53, DaVita faces challenges in effectively managing its debt levels, indicating potential financial strain.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 17.11 is lower than the industry average, implying a discounted valuation for DaVita's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.97 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 9.4, DaVita's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000927066">Check Out The Full List Of DaVita's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Javier Rodriguez Implements A Sell Strategy: Offloads $43.36M In DaVita Stock

Deep-pocketed investors have adopted a bearish approach towards DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DVA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for DaVita. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $3,042,421, and 3 are calls, amounting to $249,620.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $130.0 for DaVita over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for DaVita's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DaVita's whale activity within a strike price range from $120.0 to $130.0 in the last 30 days. 
<h3>DaVita Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1708618565_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/15/24</td>
<td>$120.00</td>
<td>$953.5K</td>
<td style="text-align: right;">307</td>
<td>4.3K</td>
</tr>
<tr>
<td>DVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/15/24</td>
<td>$120.00</td>
<td>$933.6K</td>
<td style="text-align: right;">307</td>
<td>4.3K</td>
</tr>
<tr>
<td>DVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/15/24</td>
<td>$120.00</td>
<td>$905.5K</td>
<td style="text-align: right;">307</td>
<td>4.1K</td>
</tr>
<tr>
<td>DVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$130.00</td>
<td>$118.4K</td>
<td style="text-align: right;">54</td>
<td>400</td>
</tr>
<tr>
<td>DVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$120.00</td>
<td>$111.7K</td>
<td style="text-align: right;">227</td>
<td>266</td>
</tr>
</tbody>
</table>

<h3>About DaVita</h3>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Having examined the options trading patterns of DaVita, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of DaVita</h3>
<ul>
<li>With a trading volume of 286,812, the price of DVA is down by 0.0%, reaching $120.89.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>What The Experts Say On DaVita</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $136.0.
<ul>
<li>An analyst from Truist Securities persists with their Hold rating on DaVita, maintaining a target price of $130. </li>
<li>An analyst from UBS has decided to maintain their Buy rating on DaVita, which currently sits at a price target of $145. </li>
<li>An analyst from Truist Securities has decided to maintain their Hold rating on DaVita, which currently sits at a price target of $135. </li>
<li>Maintaining their stance, an analyst from UBS continues to hold a Buy rating for DaVita, targeting a price of $134. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for DaVita, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

DaVita Options Trading: A Deep Dive into Market Sentiment

JAMES HEARTY, Chief Compliance Officer at DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), reported an insider sell on February 21, according to a new SEC filing. 
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000927066/000092706624000015//Archives/edgar/data/927066/000092706624000015/0000927066-24-000015-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday outlined that HEARTY executed a sale of 50,946 shares of DaVita with a total value of $6,100,887.
In the Wednesday's morning session, DaVita's shares are currently trading at $123.0, experiencing a down of 0.0%.
<h3>Delving into DaVita's Background</h3>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
<h3>Financial Milestones: DaVita's Journey</h3>
Revenue Growth: DaVita's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 7.85%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 32.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): DaVita's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.67.
</li>
</ul>
Debt Management: DaVita's debt-to-equity ratio is notably higher than the industry average. With a ratio of 10.53, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: DaVita's P/E ratio of 16.58 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.94 is lower than the industry average, implying a discounted valuation for DaVita's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 9.25, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000927066">Check Out The Full List Of DaVita's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JAMES HEARTY Executes Sell Order: Offloads $6.10M In DaVita Stock

Tuesday,&nbsp;Fresenius Medical Care AG&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) reported fourth-quarter 2023 revenue of €4.9 billion ($5.37 billion, almost in line with the consensus of $5.35 billion) (+7% at constant currency, +3% organic),&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">which remained flat Y/Y</a>.&nbsp;
Care Delivery revenue remained flat at €3.9 billion (+8% at constant currency, +2% organic). Care Enablement revenue declined slightly by 1% to €1.4 billion (+5% at constant currency, +6% organic). 
Higher product sales and higher average prices partly offset the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/n37209209/fresenius-medical-care-delivers-on-commitments-in-a-year-of-fundamental-transformation" rel="noreferrer noopener">negative exchange rate effects.</a>
Adjusted EPS increased 4% to €0.88 (+8% at constant currency). Adjusted EPADS reached $0.47, beating the consensus of $0.32.
As of December 31, 2023, Fresenius Medical Care treated 332,548 patients in 3,925 dialysis clinics worldwide.
In addition, the company adheres to its dividend policy of developing dividends in line with the development of net income, excluding special items. Consequently, the dividend proposal for the fiscal year 2023 of €1.19 per share corresponds to an increase of 6% compared to the prior year&#8217;s dividend.
Guidance:&nbsp;In 2024, Fresenius Medical Care expects revenue to grow by a low- to mid-single-digit percent rate compared to fiscal year 2023 sales of €19.5 billion.
The company expects operating income to grow by mid- to high-teens percent. The company reconfirms its targets to achieve an operating income margin of 10%-14% by 2025.
Citing Barclays analyst Reuters highlighted that Fresenius Medical Care forecasts fiscal year 2024 patient volume growth of 0.5%-2% compared to its rival&#8217;s&nbsp;DaVita Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) growth expectations of 1%-2%.
Barclays analysts reported a slight decrease in Fresenius Medical Care&#8217;s patient volumes from October to December compared to the previous quarter. This decline was attributed to missed treatments during the Christmas period.
Fresenius Medical Care said it sees missed treatments partly continuing in the first quarter. &#8220;We always expect Q1 to be a bit lower, but that will ramp up during the year,&#8221; Reuters noted, citing Fresenius Medical Care CEO Helen Giza.
Giza said that only about 5% of FMC patients are using GLP-1 drugs, a number that is rising at &#8220;a very, very small, small rate.&#8221;
Price Action:&nbsp;FMS shares are down 2.96% at $20.49 on the last check Tuesday.

Earnings

Guidance

Dialysis Player Fresenius Medical's Q4 Sales Hold Steady: Details

Throughout the last three months, 4 analysts have evaluated DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $136.0, with a high estimate of $145.00 and a low estimate of $130.00. Marking an increase of 9.46%, the current average surpasses the previous average price target of $124.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1708441246_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of DaVita by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DaVita. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DaVita compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DaVita's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of DaVita's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DaVita analyst ratings.</a>
<h2>Discovering DaVita: A Closer Look</h2>
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
<h3>Understanding the Numbers: DaVita's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, DaVita showcased positive performance, achieving a revenue growth rate of 7.85% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DaVita's net margin is impressive, surpassing industry averages. With a net margin of 4.79%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): DaVita's ROE stands out, surpassing industry averages. With an impressive ROE of 13.36%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): DaVita's ROA excels beyond industry benchmarks, reaching 0.89%. This signifies efficient management of assets and strong financial health.
Debt Management: DaVita's debt-to-equity ratio stands notably higher than the industry average, reaching 10.53. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DaVita Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday.
Shares of Charles River Laboratories International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crl#NYSE">CRL</a>) rose sharply during Wednesday&rsquo;s session after the company reported better-than-expected fourth-quarter results and issued <a href="https://www.benzinga.com/quote/CRL/earnings">guidance above estimates</a>.
Charles River posted adjusted earnings of $2.46 per share, beating market estimates of $2.40 per share. The company&rsquo;s quarterly sales came in at $1.01 billion versus expectations of $991.25 million.
Charles River Laboratories International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crl#NYSE">CRL</a>) rose 7.2% to $236.00 on Wednesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) shares rose 34.3% to $16.29 after the company reported fourth-quarter sales of $1.22 billion and gross bookings of $3.7 billion, up 17% year-over-year. The company&rsquo;s CFO, Erin Brewer, said the adjusted EBITDA margin is projected to expand 50 basis points in 2024.</li>
<li>Healthcare Services Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcsg#NASDAQ">HCSG</a>) rose 25.7% to $11.90 following upbeat earnings.</li>
<li>Larimar Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lrmr#NASDAQ">LRMR</a>) surged 23.9% to $10.83. Larimar Therapeutics has priced the public offering of 17.16 million shares at $8.74 per share for gross proceeds of approximately $150 million.</li>
<li>Angi Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angi#NASDAQ">ANGI</a>) climbed 22.2% to $2.97 following upbeat earnings.</li>
<li>CEVA, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ceva#NASDAQ">CEVA</a>) climbed 18.5% to $23.92 following upbeat earnings.</li>
<li>Great Lakes Dredge &amp; Dock Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gldd#NASDAQ">GLDD</a>) rose 17.1% to $9.47 following quarterly results.</li>
<li>Resideo Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rezi#NYSE">REZI</a>) jumped 16.7% to $19.94 after the company reported better-than-expected quarterly financial results.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktos#NASDAQ">KTOS</a>) rose 15.7% to $20.59 following better-than-expected quarterly results.</li>
<li>Robinhood Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) shares climbed 14.7% to $13.58 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>CleanSpark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsk#NASDAQ">CLSK</a>) rose 13.8% to $18.08 amid strength in Bitcoin.</li>
<li>United Fire Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ufcs#NASDAQ">UFCS</a>) gained 13.5% to $24.32 following upbeat results.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) jumped 13.3% to $29.13 amid strength in Bitcoin.</li>
<li>Allison Transmission Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alsn#NASDAQ">ALSN</a>) climbed 13% to $69.53 after the company reported better-than-expected quarterly financial results.</li>
<li>MRC Global Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrc#NYSE">MRC</a>) gained 12.1% to $11.64 following upbeat earnings.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) rose 11.5% to $156.50 amid strength in Bitcoin.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) gained 11.4% to $881.36.</li>
<li>Uber Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) gained 11.2% to $76.72 after the company announced an inaugural $7 billion share repurchase authorization.</li>
<li>Riot Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/riot#NASDAQ">RIOT</a>) rose 10% to $16.98 amid strength in Bitcoin.</li>
<li>IQVIA Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iqv#NYSE">IQV</a>) gained 9.7% to $236.20 following upbeat results.</li>
<li>Zillow Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/z#NASDAQ">Z</a>) gained 9.6% to $59.06 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>WESCO International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wcc#NYSE">WCC</a>) gained 9.6% to $145.32.</li>
<li>Tower Semiconductor Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsem#NASDAQ">TSEM</a>) climbed 8.5% to $31.07 following strong results.</li>
<li>Mercury General Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mcy#NYSE">MCY</a>) gained 6.6% to $43.02 following strong results.</li>
<li>DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) gained 6.4% to $120.91 following upbeat results.</li>
<li>IAC Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iac#NASDAQ">IAC</a>) rose 4.9% to $53.70 following upbeat earnings.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37126344/bitcoin-surpasses-51-000-stacks-emerges-as-top-gainer"> Bitcoin Surpasses $51,000; Stacks Emerges As Top Gainer</a>

ALSN

ANGI

CEVA

CLSK

COIN

GLDD

HCSG

HOOD

KTOS

Larimar Therapeutics, Inc. - Common Stock

LRMR

LYFT

MARA

REZI

RIOT

SMCI

TSEM

UFCS

Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday

DaVita shares are trading higher after the company reported better-than-expected Q4 financial results.

Truist Securities analyst David Macdonald maintains DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) with a Hold and raises the price target from $120 to $130.

Truist Securities Maintains Hold on DaVita, Raises Price Target to $130

DaVita Expects 2024 Adjusted EPS Of $8.70-$9.80, Est $8.68

DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) reported its Q4 earnings results on Tuesday, February 13, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
DaVita beat estimated earnings by 17.61%, reporting an EPS of $1.87 versus an estimate of $1.59.
Revenue was up $229.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.83 which was followed by a 5.89% increase in the share price the next day.
Here's a look at DaVita's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.02</td>
<td>1.66</td>
<td>1.14</td>
<td>0.91</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.85</td>
<td>2.08</td>
<td>1.58</td>
<td>1.11</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.02B</td>
<td>2.94B</td>
<td>2.84B</td>
<td>2.93B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.12B</td>
<td>3.00B</td>
<td>2.87B</td>
<td>2.92B</td>
</tr>
</tbody>
</table>

To track all earnings releases for DaVita <a href="https://www.benzinga.com/quote/DVA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DaVita: Q4 Earnings Insights

Davita Inc (DVA) is near the top in its industry group according to InvestorsObserver. DVA gets an overall rating of 78. That means it scores higher than 78 percent of stocks. Davita Inc gets a 98 rank in the Medical Care Facilities industry. Medical Care Facilities is number 52 out of 148 industries. DVA has an Overall Sc

Is Davita Inc (DVA) a Good Choice in Medical Care Facilities Tuesday?

Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues

IVV: S&P 500 Dashboard For April 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nurix Therapeutics (NRIX – Research Report) and Da...

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and DaVita (DVA)

The stock market bounced back on Wednesday and looked strong through morning trading Thursday until sellers showed up.

3 Soaring, Highly-Ranked Value Stocks To Buy In April

Top 10 best performing S&P 500 health care stocks of 2024

An announcement from DaVita (DVA) is now available. DaVita Inc. has expanded its Board of Directors, adding Dennis W. Pullin as the eleventh member...

DaVita Welcomes New Board Member and Committee Participant

In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on DaVita (DVA – Research Report), with a price target of $133.00...

Barclays Keeps Their Hold Rating on DaVita (DVA)

FHLC: Healthcare Dashboard For April

New constituents of Goldman Sachs' ROE growth basket

ABBV

ADBE

ALGN

ALKS

AMGN

AMZN

ARKG

BIIB

BLDR

CHTR

CTLT

FHLC

FOXA

HRMY

INTC

INVA

LNTH

MDLZ

MPWR

MUSA

NRIX

NXPI

PCAR

PODD

RSPH

TRGP

TRMB

Press Releases

DaVita Giving Foundation Invests $1 Million in Western Governors University to Support Nursing Students

DaVita Inc. Schedules 4th Quarter 2023 Investor Conference Call

DaVita Inc. 4th Quarter 2023 Results

DaVita Inc. to Participate in the TD Cowen's Health Care Conference 2024

Contracts

DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador

DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2024

The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On